Victoria Soldatenkova Selected Research

necitumumab

11/2019	A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer.
1/2018	Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis.
10/2017	Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study.
6/2016	The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial.
1/2016	Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE).
3/2015	Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Victoria Soldatenkova Research Topics

Disease

13	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2021 - 05/2006
5	Disease Progression 10/2017 - 08/2012
4	Thrombocytopenia (Thrombopenia) 01/2022 - 05/2013
4	Breast Neoplasms (Breast Cancer) 05/2013 - 03/2005
3	Neutropenia 06/2016 - 05/2013
2	Neoplasms (Cancer) 01/2022 - 01/2016
2	Fatigue 01/2022 - 05/2013
2	Exanthema (Rash) 01/2022 - 03/2015
2	Sarcoma (Soft Tissue Sarcoma) 01/2022 - 01/2020
2	Adenocarcinoma 08/2012 - 11/2010
1	Drug Hypersensitivity (Drug Allergy) 01/2022
1	Fever (Fevers) 01/2022
1	Hypersensitivity (Allergy) 01/2022
1	Hypotension (Low Blood Pressure) 01/2022
1	Pain (Aches) 01/2022
1	Tachycardia (Tachyarrhythmias) 01/2022
1	Arthralgia (Joint Pain) 01/2022
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 03/2021
1	Leiomyosarcoma 01/2020
1	Venous Thromboembolism 01/2018
1	Anemia 05/2013
1	Transitional Cell Carcinoma 09/2009
1	Non-Muscle Invasive Bladder Neoplasms 09/2009
1	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 07/2006
1	Wounds and Injuries (Trauma) 07/2006

Drug/Important Bio-Agent (IBA)

9	Cisplatin (Platino)FDA LinkGeneric 03/2021 - 05/2006
8	Pemetrexed (MTA)FDA Link 03/2021 - 11/2010
8	Gemcitabine FDA Link 10/2017 - 03/2005
6	necitumumabIBA 11/2019 - 03/2015
3	Carboplatin (JM8)FDA LinkGeneric 03/2021 - 05/2013
2	selpercatinibIBA 01/2022 - 03/2021
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 01/2020
2	taxaneIBA 05/2013 - 03/2012
2	Docetaxel (Taxotere)FDA Link 08/2012 - 11/2010
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 08/2012 - 11/2010
2	Epirubicin (Ellence)FDA LinkGeneric 12/2008 - 03/2005
1	Alanine Transaminase (SGPT)IBA 01/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022
1	CreatinineIBA 01/2022
1	Phosphotransferases (Kinase)IBA 01/2022
1	pembrolizumabIBA 03/2021
1	olaratumabIBA 01/2020
1	abemaciclibIBA 11/2019
1	Monoclonal AntibodiesIBA 01/2018
1	Immunoglobulin G (IgG)IBA 01/2016
1	ErbB Receptors (EGF Receptor)IBA 01/2016
1	Vinorelbine (Navelbine)FDA LinkGeneric 05/2013
1	AnthracyclinesIBA 05/2013
1	Pharmaceutical PreparationsIBA 05/2013
1	Taxoids (Taxanes)IBA 03/2012
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 12/2008
1	Fluoxetine (Prozac)FDA LinkGeneric 07/2006
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 03/2005
1	Fluorouracil (Carac)FDA LinkGeneric 03/2005
1	Paclitaxel (Taxol)FDA LinkGeneric 03/2005

Therapy/Procedure

9	Therapeutics 01/2022 - 03/2005
5	Drug Therapy (Chemotherapy) 03/2021 - 03/2005
2	Adjuvant Chemotherapy 12/2015 - 12/2008
1	Induction Chemotherapy 05/2013
1	Radiotherapy 05/2013
1	Chemoradiotherapy 05/2013
1	Secondary Prevention 07/2006